|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000175745 |
Summary for NR2F1 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000175745 | Gene symbol | NR2F1 |
| Gene name | nuclear receptor subfamily 2 group F member 1 | |
| HGNC | 7975 | |
| Entrez ID | 7025 | |
| Gene type | protein_coding | |
| Synonyms | NR2F1|EAR-3|COUP-TFI|TCFCOUP1|SVP44|COUPTF1 | |
| UniProtAcc | P10589 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000175745 | NR2F1 | DB06732 | beta-Naphthoflavone | SmallMoleculeDrug |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NR2F1 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NR2F1 | 8.57e+02 | -1.15e+00 | 4.64e-01 | -2.49e+00 | 1.29e-02 | 3.09e-02 | CHOL |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NR2F1 | 2.12e+03 | -1.51e+00 | 4.21e-01 | -3.58e+00 | 3.42e-04 | 2.41e-03 | STAD |
Top |
Sex-biased somatic mutation for NR2F1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NR2F1 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16995983 | chr5:93584790 | CGI:chr5:93583852-93585724 | UTR,promoter,exon,gene body | 6.31e-02 | 2.56e-01 | -2.08e+00 | 3.76e-02 | 4.48e-02 | -1.93e-01 |
| BRCA | cg12207450 | chr5:93583629 | CGI:chr5:93583852-93585724 | UTR,promoter,exon,gene body | 1.96e-01 | 3.17e-01 | -2.02e+00 | 4.39e-02 | 4.76e-02 | -1.21e-01 |
| BRCA | cg07875786 | chr5:93583221 | CGI:chr5:93583852-93585724 | promoter | 4.15e-01 | 5.56e-01 | -2.05e+00 | 4.03e-02 | 4.61e-02 | -1.41e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg07875786 | chr5:93583221 | CGI:chr5:93583852-93585724 | promoter | 2.26e-01 | 3.27e-01 | -3.94e+00 | 8.31e-05 | 2.22e-04 | -1.01e-01 |
| KIRP | cg08806496 | chr5:93583237 | CGI:chr5:93583852-93585724 | promoter | 2.28e-01 | 4.57e-02 | 2.79e+00 | 5.34e-03 | 7.53e-03 | 1.82e-01 |
| KIRP | cg05945291 | chr5:93583142 | CGI:chr5:93583852-93585724 | promoter | 2.67e-01 | 9.12e-02 | 4.63e+00 | 3.70e-06 | 1.62e-05 | 1.76e-01 |
| KIRP | cg11904056 | chr5:93583204 | CGI:chr5:93583852-93585724 | promoter | 2.63e-01 | 1.06e-01 | 3.48e+00 | 5.02e-04 | 1.02e-03 | 1.57e-01 |
| KIRP | cg03086663 | chr5:93583206 | CGI:chr5:93583852-93585724 | promoter | 2.99e-01 | 1.41e-01 | 3.40e+00 | 6.78e-04 | 1.31e-03 | 1.59e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg08806496 | chr5:93583237 | CGI:chr5:93583852-93585724 | promoter | 2.74e-01 | 9.94e-02 | 4.87e+00 | 1.13e-06 | 2.09e-06 | 1.75e-01 |
| BRCA | cg11904056 | chr5:93583204 | CGI:chr5:93583852-93585724 | promoter | 3.34e-01 | 2.11e-01 | 3.40e+00 | 6.83e-04 | 9.17e-04 | 1.23e-01 |
| BRCA | cg07875786 | chr5:93583221 | CGI:chr5:93583852-93585724 | promoter | 4.15e-01 | 2.97e-01 | 5.52e+00 | 3.44e-08 | 7.33e-08 | 1.18e-01 |
| BLCA | cg07875786 | chr5:93583221 | CGI:chr5:93583852-93585724 | promoter | 1.96e-01 | 3.04e-01 | -3.35e+00 | 8.15e-04 | 4.41e-03 | -1.08e-01 |
Top |
Exon skipping events with PSI in TCGA for NR2F1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NR2F1 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NR2F1 |
TFs related to NR2F1.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MESO | ZNF418 | NR2F1 | 1.90e+00 | 1.82e-04 | 4.23e+00 | 9.89e-01 | Female-biased |
NR2F1 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NR2F1 |
RBPs related to ES in NR2F1.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
NR2F1 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12186366 | chr5:96753146:A:G | - | 0.0759491932488253 | 0.0454494408539501 | LUAD | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs57425975 | chr5:102860309:C:A | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs7704560 | chr5:102860452:G:A | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs73192721 | chr5:102862600:G:A | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs73192723 | chr5:102862678:T:C | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs73192724 | chr5:102862760:A:G | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs9687982 | chr5:102864258:A:G | - | 0.164864821899654 | 0.00422958986999195 | THCA | Male-baised eQTL |
| rs16901910 | chr5:85751217:A:C | - | 0.14323734746451 | 0.00570330170507828 | THCA | Male-baised eQTL |
| rs77182073 | chr5:92987515:T:C | - | 0.162221612271912 | 0.0342522654878338 | THCA | Male-baised eQTL |
| rs10054183 | chr5:85202378:C:T | - | 0.10070682986521 | 0.011067060491673 | KIRC | Male-baised eQTL |
| rs13355623 | chr5:85203458:C:T | - | 0.10070682986521 | 0.011067060491673 | KIRC | Male-baised eQTL |
| rs73770003 | chr5:85207149:A:G | - | 0.10070682986521 | 0.011067060491673 | KIRC | Male-baised eQTL |
| rs10064805 | chr5:85207270:C:A | - | 0.10070682986521 | 0.011067060491673 | KIRC | Male-baised eQTL |
| rs10035694 | chr5:85208589:A:G | - | 0.10070682986521 | 0.011067060491673 | KIRC | Male-baised eQTL |
| rs4610491 | chr5:85208947:G:A | - | 0.100143912844092 | 0.0132803891389054 | KIRC | Male-baised eQTL |
| rs6452643 | chr5:85204357:G:A | - | 0.099758860039108 | 0.0137774323727587 | KIRC | Male-baised eQTL |
| rs10067283 | chr5:85118316:G:A | - | 0.106836024487849 | 0.0155618211265041 | KIRC | Male-baised eQTL |
| rs4608955 | chr5:85207681:G:A | - | 0.0920834686261769 | 0.0258227858198174 | KIRC | Male-baised eQTL |
| rs10056414 | chr5:85143202:G:A | - | 0.0893796325847474 | 0.0492408033202261 | KIRC | Male-baised eQTL |
| rs115054593 | chr5:91216482:A:T | - | 0.0675187732473865 | 0.0147618004004689 | BLCA | Male-baised eQTL |
| rs185025618 | chr5:91216483:A:C | - | 0.0675187732473865 | 0.0147618004004689 | BLCA | Male-baised eQTL |
| rs7729487 | chr5:84586737:A:G | - | 0.0657106429773568 | 0.0178904840221492 | BLCA | Male-baised eQTL |
| rs28690145 | chr5:84593607:A:G | - | 0.0638781331062629 | 0.0251849987320226 | BLCA | Male-baised eQTL |
| rs13356047 | chr5:84591781:G:A | - | 0.062344134449009 | 0.027398994709905 | BLCA | Male-baised eQTL |
| rs56017528 | chr5:84387860:T:C | - | 0.0730836105968643 | 0.00563969425141601 | LUAD | Male-baised eQTL |
| rs2352204 | chr5:98054706:T:C | - | 0.0616333380121787 | 0.0060935332703467 | LUAD | Male-baised eQTL |
| rs7732196 | chr5:98049737:A:C | - | 0.0610305736942009 | 0.00672932324588605 | LUAD | Male-baised eQTL |
| rs35321390 | chr5:98054018:A:G | - | 0.0610305736942009 | 0.00672932324588605 | LUAD | Male-baised eQTL |
| rs72766433 | chr5:84410075:C:T | - | 0.0744871653820294 | 0.012855331223203 | LUAD | Male-baised eQTL |
| rs6877492 | chr5:84384032:C:T | - | 0.0639655366793444 | 0.0182967622617807 | LUAD | Male-baised eQTL |
| rs7720807 | chr5:84336873:A:G | - | 0.0494739376033243 | 0.0189021918072416 | LUAD | Male-baised eQTL |
| rs34703116 | chr5:98057934:A:C | - | 0.0528319324576143 | 0.0289335463474129 | LUAD | Male-baised eQTL |
| rs7717950 | chr5:98062186:T:A | - | 0.0495411393401939 | 0.0488979036459417 | LUAD | Male-baised eQTL |
| rs74394630 | chr5:86773007:T:C | - | -0.0535558673035476 | 0.0289832570376792 | COAD | Male-baised eQTL |
| rs1592867 | chr5:86769373:T:G | - | -0.0519581465905837 | 0.0339022276894467 | COAD | Male-baised eQTL |
| rs1582457 | chr5:86769800:A:G | - | -0.0519581465905837 | 0.0339022276894467 | COAD | Male-baised eQTL |
| rs1120186 | chr5:86777387:A:G | - | -0.0520576124282278 | 0.0416853092779842 | COAD | Male-baised eQTL |
| rs10051603 | chr5:86771322:G:T | - | -0.0510666508774352 | 0.0462042114351961 | COAD | Male-baised eQTL |
| rs10060205 | chr5:86768515:A:C | - | -0.050163330407643 | 0.0492079736745243 | COAD | Male-baised eQTL |
| rs10075365 | chr5:86768633:G:C | - | -0.050163330407643 | 0.0492079736745243 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08690999 | chr5:93587690 | gene,enhancer | -0.352537929050933 | 2.12483823373638e-05 | -0.37657711270000965 | 3.5927755991477304e-08 | KIRP |
| cg15171839 | chr5:93588897 | gene | -0.332140003754588 | 1.0680022310197e-11 | -0.446580243723036 | 6.1955579103525455e-15 | LUSC |
| cg08690999 | chr5:93587690 | gene,enhancer | -0.468439849325044 | 2.65512739266794e-18 | -0.5110630407733093 | 1.0753939773677474e-21 | BLCA |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg04192879 | chr5:93593767 | gene,exon,CDS | 0.0478644900453074 | 8.40539268546142e-07 | 0.3002836720190038 | 4.17719005105656e-09 | THCA |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NR2F1 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000175745 | NR2F1 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C0010093 | Corpus Luteum Cyst | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C0029927 | Ovarian Cysts | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C3810363 | Optic atrophy, intellectual disability syndrome | 1 | CTD_human |
| ENSG00000175745 | NR2F1 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |